X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of the deal, Samsung Biologics will provide antibody development and drug substance manufacturing services as a part of LegoChem Biosciences' ADC program, including LCB73, a CD19-targeted ADC candidate for hematological tumors.
Lead Product(s): LCB73
Therapeutic Area: Oncology Product Name: LCB73
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Samsung Biologics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 07, 2024
Details:
The net proceeds will be used to advance Lego's ADC pipeline including, LCB14, an antibody-drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2).
Lead Product(s): LCB14
Therapeutic Area: Oncology Product Name: LCB14
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Orion Corporation
Deal Size: $410.9 million Upfront Cash: Undisclosed
Deal Type: Financing January 16, 2024
Details:
Under the terms of the agreement, LCB will grant Janssen an exclusive, worldwide license for the development and commercialization of LCB84, a Trop2 directed ADC which is currently being investigated for advanced solid tumors.
Lead Product(s): LCB84,Undisclosed
Therapeutic Area: Oncology Product Name: LCB84
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: JANSSEN BIOTECH
Deal Size: $1,700.0 million Upfront Cash: $100.0 million
Deal Type: Licensing Agreement December 26, 2023
Details:
Under the collaboration, BostonGene will support the Phase I/II study of LCB84, a TROP2-directed antibody-drug conjugate (ADC), in patients with advanced cancers.
Lead Product(s): LCB84,Anti-PD-1 Ab
Therapeutic Area: Oncology Product Name: LCB84
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: BostonGene
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 07, 2023
Details:
The agreement aims to develop an antibody drug conjugate by combining LCB’s proprietary ADC technology with one of Glycotope’s investigational antibodies. LCB has worldwide exclusive rights to develop and commercialize the selected antibody as an ADC.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Recipient: Glycotope
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 16, 2023
Details:
Under the terms of the licensing agreement, LegoChem Biosciences will develop and commercialize a novel antibody-drug conjugate (ADC) therapy using a monoclonal antibody developed by Elthera.
Lead Product(s): Antibody-drug Conjugate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Recipient: Elthera
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 13, 2023
Details:
LCB’s clinical-stage ConjuAll Antibody Drug Conjugates (ADC) technology platform provides optimized site-specific conjugation, as well as cancer-selectively activating linker and payload technologies for ADCs.
Lead Product(s): Antibody-drug Conjugate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Amgen Inc
Deal Size: $1,250.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration December 23, 2022
Details:
SOT106 is a novel ADC based on SOTIO Biotech’s proprietary antibodies and LCB’s industry-leading ConjuAll™ ADC platform technology with potential best-in class efficacy, safety and tolerability currently in preclinical development against multiple solid tumor indications.
Lead Product(s): SOT106
Therapeutic Area: Oncology Product Name: SOT106
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Sotio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 29, 2022
Details:
The parties will utilize their respective product development capabilities to generate the B7-H4 ADC and advance it to the clinic. In addition, there are options for the parties to nominate two additional targets for ADC development beyond B7-H4.
Lead Product(s): NC762
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Recipient: NextCure
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 15, 2022
Details:
Glycotope’s antibodies target specific tumor-associated carbohydrate structures or protein/carbohydrate combined glyco-epitopes (GT-00X). Targeting these specific antigens enables broad indication range, long-term treatment potential and reduced on-target/off tumor toxicity.
Lead Product(s): Antibody Drug Conjugate
Therapeutic Area: Oncology Product Name: GT-00X
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Glycotope
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 12, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
